×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Myeloma

Featured Content
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
Ryan McDonald
CC-92480, a novel cereblon E3 ligase modulator agent, in combination with dexamethasone appeared safe and active in patients with heavily pretreated relapsed or refractory multiple myeloma, according to data presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
 
Beth Fand Incollingo
The addition of the novel drug Xpovio to the regimen of Velcade and dexamethasone delayed disease progression, reduced peripheral neuropathy and required fewer office visits in a study of previously treated patients with multiple myeloma.
 
Jessica Skarzynski
New findings, presented at the 2020 ASCO Virtual Scientific Program, suggest that the standard of care for newly diagnosed patients with multiple myeloma remains superior to the Kyprolis triplet therapy.
 
CURE Staff
In the first installment of CURE®’s inaugural webinar series, “Hear from the Experts: COVID-19 & Cancer Care for Patients”, Dr. Farukh Awan addresses how the new coronavirus has impacted patient care for those diagnosed with chronic lymphocytic leukemia and myeloma.
 
Ryan McDonald
The Food and Drug Administration approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a subcutaneous form of Darzalex, for adults with newly diagnosed or relapsed/refractory multiple myeloma.
 
Ryan McDonald
Here is a list of the recent trial initiations that occurred within the cancer space in April.
 
Sally Kalksma
“Only you have the power to make your life better,” says a myeloma survivor on living for the moment after a cancer diagnosis.
 
Ryan McDonald
A new genetic test that identifies patients with multiple myeloma who have high-risk genetics may help oncologists find alternative treatment options before the disease progresses. 
Sally Kalksma
“I just want people to know that when they say you have cancer, they are not saying you have a death sentence. You can still live and you can live well.”
 
Ryan McDonald
Patients with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy experienced a durable clinical benefit after receiving melflufen (Oncopeptides) in combination with dexamethasone.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×